

TUESDAY 26TH NOVEMBER

18:30: WELCOME

19:00: PROF. DR. COLLINS

19:30: PROF. DR. VERHAMME

RADISSON BLU ROYAL HOTEL BRUSSELS

WOLVENGRACHT 47 - 1000 BRUSSEL

RUE DU FOSSÉ AUX LOUPS 47 - 1000 BRUXELLES

**ORAL ANTICOAGULATION
IN THE AGEING AF PATIENTS
FROM GUIDELINES TO DAILY PRACTICE**

Prof. dr. Collins

**THE COMPLEXITY OF THE TREATMENT
OF AGEING PATIENTS WITH VTE**

Prof. dr. Verhamme

MODERATOR

Prof. dr. Flamaing - Co-president BSGG

TUESDAY 26TH NOVEMBER

18:30: Welcome

19:00: Prof. dr. Collins

19:30: Prof. dr. Verhamme

RADISSON BLU ROYAL HOTEL BRUSSELS

WOLVENGRACHT 47 - 1000 BRUSSEL

RUE DU FOSSÉ AUX LOUPS 47 - 1000 BRUXELLES



Prof. dr. Rónán Collins (MD, FRCP (Lond), FRCPI, FESO) graduated from the University College Cork in 1992 and completed his higher medical training in Geriatric Medicine at Trinity College Dublin and the Yorkshire deanery at Leeds UK in 2002. He was appointed consultant in Geriatric and stroke medicine Tallaght University Hospital Dublin in 2005 and a clinical associate professor in geriatric medicine in 2017. He is National PI on ENOS, TICH-2 trials, BLITZ-AF and Gloria-AF registry.

He was Director of stroke services at the hospital from 2005 to 2017, project lead on the successful inaugural Dublin mid-leinster stroke telemedicine project and current Royal College of Physicians National Clinical Lead in Stroke. He is a member of the European Heart Rhythm Association (EHRA) writing group for the practical guide to NOAC use and runs an interdisciplinary atrial fibrillation clinic.

Professor Collins is a keen fisherman, lover of sport of hurling, environmentalist and a promoter of patient narrative and intergenerational connectivity. His special clinical and research interests include stroke, atrial fibrillation, arts in health, dementia & reminiscence and telemedicine.



Prof. dr. Peter Verhamme (MD, PhD) is a physician at the Department of Cardiovascular Medicine, Vascular Medicine and Haemostasis Unit of the University Hospitals Leuven, Belgium. His main clinical interests and clinical research programmes concern the prevention and treatment of venous and arterial thrombosis. He is also principal investigator of research programmes at the Center for Molecular and Vascular Biology, University of Leuven, focussing on new fibrinolytic and antithrombotic strategies, and on the interactions between infection and coagulation.

He obtained his MD at the University of Leuven in 1997, and completed a PhD on oxidized low-density lipoprotein and atherothrombosis. Professor Verhamme has co-authored more than 250 papers published in peer-reviewed journals.